Table 3.
Use of Antihypertensive Agents in Patients With Not‐At‐Goal Hypertension
| Overall (N=7032) | One Agent (n=5232) | Two Agents (n=1397) | Three Agents (n=340) | Four or More Agents (n=63) | P Value | |
|---|---|---|---|---|---|---|
| Diuretics, No. (%) | 2048 (29.1) | 1134 (21.7) | 624 (22.3) | 233 (23.8) | 57 (22.6) | .81 |
| Anti‐RAS system agents, No. (%) | 4232 (60.2) | 3013 (57.6) | 979 (70.1) | 277 (81.5) | 53 (84.1) | <.001 |
| Calcium channelblocker, No. (%) | 2120 (30.2) | 1102 (21.1) | 724 (25.9) | 243 (23.8) | 51 (20.3) | <.001 |
| Antiadrenergic agents, No. (%) | 1385 (19.7) | 441 (8.4) | 627 (44.9) | 254 (74.7) | 63 (100.0) | <.001 |
Values are presented as numbers (percentage). Anti–renin‐angiotensin‐aldosteronism (RAS) system agents include angiotensin‐converting enzyme inhibitors, angiotensin receptor inhibitors, and renin inhibitors. Antiadrenergic agents include β‐blockers and central‐acting agents.